March 30 (Reuters) - Viridian Therapeutics said on Monday its experimental drug met the main goal in late-stage study, when tested in patients with active thyroid eye disease. The injectable drug, ...
Viridian Therapeutics shares slumped 34% to an eight-month low on Monday after its experimental treatment for thyroid eye disease lagged rivals in efficacy in a late-stage study, even as it met the ...
Shares of Viridian Therapeutics (NASDAQ:VRDN) fell more than 30% Monday morning following the release of topline results from ...
Thyroid eye disease can cause eye pain, dryness, and eyelids that do not fully close. These symptoms can disrupt sleep. When your eyes stay partly open at night, light and dryness can make it harder ...
Dear Doctors: Lately, we’ve been seeing a lot of ads on TV for a medication to treat thyroid eye disease. My daughter, who is 23, suffers from dry eyes, and now she’s sure she has it. What is thyroid ...
Researchers in Korea recently identified predictive factors for normalization of thyroid-stimulating immunoglobulin levels in moderate-to-severe Graves’ orbitopathy, highlighting the importance of ...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...
Thyroid eye disease (TED), also known as Graves’ eye disease, usually stems from an autoimmune condition that starts when immune cells attack the thyroid gland, a tiny butterfly-shaped gland at the ...
Please provide your email address to receive an email when new articles are posted on . Prevent Blindness has declared Sept. 16 to 22 as Inflammatory Eye Disease Awareness Week and is offering free ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Fibroblasts from patients with TED secrete active PAPP-A and are stimulated by proinflammatory cytokines, namely tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Novel therapeutic agents may be ...
14hon MSN
Viridian's thyroid eye disease drug succeeds in late‑stage trial but falls short of expectations
By Siddhi Mahatole March 30 (Reuters) - Viridian Therapeutics said on Monday its experimental drug met the main goal in a late-stage study, when tested in patients with active thyroid eye disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results